AVBP
ArriVent BioPharma, Inc. Common Stock
NASDAQ: AVBP · HEALTHCARE · BIOTECHNOLOGY
$15.95
+1.40% today
Updated 2026-10-29
Market cap
$884.58M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.62
Dividend yield
—
52W range
$11 – $36
Volume
1.4M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
4.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$21.56
+35.17%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.75 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-39.58M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-36.91M | $-69.33M | $-80.49M | $-166.31M | $-49.89M |
| EPS | — | — | — | — | $-3.62 |
| Free cash flow | $-43.63M | $-55.84M | $-70.21M | $-160.59M | $-39.58M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
ArriVent BioPharma, Inc. Common Stock trades at $15.95. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 4.75, it sits in the safe zone.
Frequently asked questions
What is ArriVent BioPharma, Inc. Common Stock's stock price?
ArriVent BioPharma, Inc. Common Stock (AVBP) trades at $15.95.
Is ArriVent BioPharma, Inc. Common Stock overvalued?
ArriVent BioPharma, Inc. Common Stock carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of ArriVent BioPharma, Inc. Common Stock (AVBP)?
The 12-month analyst consensus target is $21.56, about 35.2% above the current $15.95. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
ArriVent BioPharma, Inc. Common Stock's Altman Z-Score is 4.75, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-44.63%
Beta1.35
50D MA$27.33
200D MA$27.11
Shares out0.05B
Float0.03B
Short ratio—
Avg volume1.4M
Performance
1 week-18.07%
1 month-46.75%
3 months-48.70%
YTD-21.82%
1 year-15.79%
3 years—
5 years—